HC Wainwright Trims Trevena (TRVN) Target Price to $3.00

Trevena (NASDAQ:TRVN) had its price objective cut by research analysts at HC Wainwright from $7.00 to $3.00 in a research note issued on Friday, Stock Target Advisor reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 240.87% from the stock’s current price.

TRVN has been the subject of a number of other research reports. Zacks Investment Research upgraded Trevena from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a research note on Friday, August 17th. Needham & Company LLC lowered Trevena from a “buy” rating to a “hold” rating in a research note on Friday. Jefferies Financial Group lowered Trevena from a “buy” rating to a “hold” rating and reduced their price objective for the company from $10.00 to $1.00 in a research note on Wednesday. Finally, JMP Securities lifted their price objective on Trevena from $4.00 to $15.00 and gave the company an “outperform” rating in a research note on Friday. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $5.66.

NASDAQ TRVN opened at $0.88 on Friday. The stock has a market cap of $161.29 million, a price-to-earnings ratio of -0.73 and a beta of -0.38. Trevena has a fifty-two week low of $0.76 and a fifty-two week high of $3.58. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 0.28.

Trevena (NASDAQ:TRVN) last released its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.13). The company had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $5.50 million. Analysts forecast that Trevena will post -0.61 EPS for the current year.

Several institutional investors have recently made changes to their positions in the stock. Northern Trust Corp increased its stake in shares of Trevena by 6.6% in the 1st quarter. Northern Trust Corp now owns 579,697 shares of the biopharmaceutical company’s stock valued at $950,000 after purchasing an additional 35,967 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of Trevena by 55.0% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 144,362 shares of the biopharmaceutical company’s stock valued at $237,000 after purchasing an additional 51,200 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Trevena by 635.7% in the 1st quarter. JPMorgan Chase & Co. now owns 89,228 shares of the biopharmaceutical company’s stock valued at $146,000 after purchasing an additional 77,100 shares in the last quarter. LMR Partners LLP purchased a new position in shares of Trevena in the 2nd quarter valued at about $207,000. Finally, GSA Capital Partners LLP increased its stake in shares of Trevena by 186.2% in the 2nd quarter. GSA Capital Partners LLP now owns 351,847 shares of the biopharmaceutical company’s stock valued at $507,000 after purchasing an additional 228,900 shares in the last quarter. Hedge funds and other institutional investors own 43.08% of the company’s stock.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure.

Featured Story: How to Invest in Marijuana Stocks

Stock Target Advisor

Analyst Recommendations for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply